The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia

John D. McConnell, Reginald Bruskewitz, Patrick Walsh, Gerald Andriole, Michael Lieber, H. Logan Holtgrewe, Peter Albertsen, Claus G. Roehrborn, J. Curtis Nickel, Daniel Z. Wang, Alice M. Taylor, Joanne Waldstreicher

Research output: Contribution to journalArticle

Abstract

Background. Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, are not known. Methods. In this double-blind, randomized, placebo- controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. Results. During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalNew England Journal of Medicine
Volume338
Issue number9
DOIs
StatePublished - Feb 26 1998

Fingerprint

Finasteride
Urinary Retention
Prostatic Hyperplasia
Placebos
Therapeutics
Risk Reduction Behavior
Prostate
Confidence Intervals
Randomized Controlled Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. / McConnell, John D.; Bruskewitz, Reginald; Walsh, Patrick; Andriole, Gerald; Lieber, Michael; Logan Holtgrewe, H.; Albertsen, Peter; Roehrborn, Claus G.; Nickel, J. Curtis; Wang, Daniel Z.; Taylor, Alice M.; Waldstreicher, Joanne.

In: New England Journal of Medicine, Vol. 338, No. 9, 26.02.1998, p. 557-563.

Research output: Contribution to journalArticle

McConnell, JD, Bruskewitz, R, Walsh, P, Andriole, G, Lieber, M, Logan Holtgrewe, H, Albertsen, P, Roehrborn, CG, Nickel, JC, Wang, DZ, Taylor, AM & Waldstreicher, J 1998, 'The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia', New England Journal of Medicine, vol. 338, no. 9, pp. 557-563. https://doi.org/10.1056/NEJM199802263380901
McConnell, John D. ; Bruskewitz, Reginald ; Walsh, Patrick ; Andriole, Gerald ; Lieber, Michael ; Logan Holtgrewe, H. ; Albertsen, Peter ; Roehrborn, Claus G. ; Nickel, J. Curtis ; Wang, Daniel Z. ; Taylor, Alice M. ; Waldstreicher, Joanne. / The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. In: New England Journal of Medicine. 1998 ; Vol. 338, No. 9. pp. 557-563.
@article{a3bd974448e24828bed891cb8abbfb86,
title = "The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia",
abstract = "Background. Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, are not known. Methods. In this double-blind, randomized, placebo- controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. Results. During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P",
author = "McConnell, {John D.} and Reginald Bruskewitz and Patrick Walsh and Gerald Andriole and Michael Lieber and {Logan Holtgrewe}, H. and Peter Albertsen and Roehrborn, {Claus G.} and Nickel, {J. Curtis} and Wang, {Daniel Z.} and Taylor, {Alice M.} and Joanne Waldstreicher",
year = "1998",
month = "2",
day = "26",
doi = "10.1056/NEJM199802263380901",
language = "English (US)",
volume = "338",
pages = "557--563",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia

AU - McConnell, John D.

AU - Bruskewitz, Reginald

AU - Walsh, Patrick

AU - Andriole, Gerald

AU - Lieber, Michael

AU - Logan Holtgrewe, H.

AU - Albertsen, Peter

AU - Roehrborn, Claus G.

AU - Nickel, J. Curtis

AU - Wang, Daniel Z.

AU - Taylor, Alice M.

AU - Waldstreicher, Joanne

PY - 1998/2/26

Y1 - 1998/2/26

N2 - Background. Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, are not known. Methods. In this double-blind, randomized, placebo- controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. Results. During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P

AB - Background. Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, are not known. Methods. In this double-blind, randomized, placebo- controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. Results. During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P

UR - http://www.scopus.com/inward/record.url?scp=0006075228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006075228&partnerID=8YFLogxK

U2 - 10.1056/NEJM199802263380901

DO - 10.1056/NEJM199802263380901

M3 - Article

VL - 338

SP - 557

EP - 563

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -